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Purpose: To evaluate selective apoptosis of Y79 retinoblastoma versus ARPE-19
retinal pigment epithelial cells by using different doses of dextran-coated iron oxide
nanoparticles (DCIONs) in a magnetic hyperthermia paradigm.
Methods: Y79 and ARPE-19 cells were exposed to different concentrations of DCIONs,
namely, 0.25, 0.5, 0.75, and 1 mg/ml. After 2 hours of incubation, cells were exposed to
a magnetic field with a frequency of 250 kHz and an amplitude of 4 kA/m for 30
minutes to raise the cellular temperature between 42 and 468C. Y79 and ARPE-19 cells
incubated with DCION without magnetic field exposure were used as controls. Cell
viability and apoptosis were assessed at 4, 24, and 72 hours after hyperthermia
treatment.
Results: At 4 hours following magnetic hyperthermia, cell death for Y79 cells was 1%,
8%, 17%, and 17% for 0.25, 0.5, 0.75 and 1 mg/ml of DCION, respectively. Cell death
increased to 47%, 59%, 70%, and 75% at 24 hours and 16%, 45%, 50%, and 56% at 72
hours for 0.25, 0.5, 0.75, and 1 mg/ml of DCIONs, respectively. Magnetic hyperthermia
did not have any significant toxic effects on ARPE-19 cells at all DCION concentrations,
and minimal baseline cytotoxicity of DCIONs on Y79 and ARPE-19 cells was observed
without magnetic field activation. Gene expression profiling showed that genes
involved in FAS and tumor necrosis factor alpha signaling pathways were activated in
Y79 cells following hyperthermia. Caspase 3/7 activity in Y79 cells increased following
treatment, consistent with the activation of caspase-mediated apoptosis and loss of
cell viability by magnetic hyperthermia.
Conclusion: Magnetic hyperthermia using DCIONs selectively kills Y79 cells at 0.5 mg/
ml or higher concentrations via the activation of apoptotic pathways.
Translational Relevance: Magnetic hyperthermia using DCIONs might play a role in
targeted management of retinoblastoma.
Introduction
Retinoblastoma is one of the most common
malignant intraocular tumors in children. In the
United States, it is estimated that about 12 children
per million under the age of 5 years are affected by
this cancer.1 In recent years, significant progress has
been made in the treatment of retinoblastoma with
the introduction of intra-arterial and intravitreal
chemotherapy, and as a result, the survival rate
reached above 90% in developed countries.2,3 A recent
literature review showed that the globe salvage rate is
90% to 100% for groups A to C eyes, more than 70%
for group D eyes, and 51% for group E eyes following
the intra-arterial chemotherapy. The primary reason
for treatment failure in groups D and E was the
presence of intravitreous seeds. Intra-arterial chemo-
therapy requires an experienced team and advanced
equipment, which are limited to few centers.4,5 With
the recent development of safe injection techniques,
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intravitreal injections of the chemotherapeutic agents
melphalan and topotecan are being used more
commonly. However, intravitreal chemotherapy has
the potential to cause ocular toxicity. Therefore, there
is an unmet need for new retinoblastoma treatment
modalities with a better safety and efficacy profile.
Nanoparticles of various materials can enhance
intraocular drug delivery and retention and may have
the potential to improve retinoblastoma treatment.6,7
Most systems used for drug delivery applications are
colloidal suspensions consisting of nanoparticles with a
diameter ranging from 10 to 1000 nm, in which the
therapeutic agent can be encapsulated or conjugated
on the surface of the nanoparticles. Mitra et al.8
demonstrated that etoposide-loaded poly(lactide-co-
glycolide) nanoparticles show 100 times greater anti-
proliferative and apoptotic gene activity in Y79
retinoblastoma cells compared to native etoposide,
indicating the potential of a nanoparticle platform as
novel chemotherapy delivery system for retinoblasto-
ma. Similarly, Ahmed et al.9 reported that carboplatin-
loaded protein nanoparticles had greater intracellular
uptake and sustained retention, increasing the antipro-
liferative activity on retinoblastoma cells compared to
their soluble counterpart. Qu et al.2 studied the efficacy
of topotecan-loaded mesoporous silica nanoparticles
that were surface conjugated with folic acid for the
treatment of retinoblastoma. These nanoparticles
showed a remarkable uptake in cells compared to the
nontargeted nanoparticles, and higher cytotoxicity was
observed on retinoblastoma cells. Chitosan nanoparti-
cles, which are biocompatible, relatively nontoxic, and
biodegradable in nature,10 have been used by some
researchers due to their improved mucoadhesiveness
and ability to cross the epithelial junction. Manasi Das
et al.11 encapsulated anticancer drug nutlin-3a and
chemosensitizer curcumin in polylactic-co-glycolic acid
nanoparticles, which were surface functionalized with
folate to enhance the therapeutic potential and prevent
multidrug resistance. Beside polylactic-co-glycolic acid
nanoparticles, lipid nanoparticles have been used to
codeliver miR-181a and melphalan to retinoblastoma
cell lines to decrease the expression of the antiapoptotic
gene BCL2 while increasing the expression of proa-
poptotic gene BAX, thus making the cells more
sensitive to melphalan treatment.12
Magnetic nanoparticles have recently emerged as a
potential modality for the diagnosis and the treatment
of cancer.13 Super paramagnetic nanoparticles of iron
oxide have proven particularly beneficial for potential
cancer treatment. These materials are also called
multifunctional ferrofluids, which are highly stable in
aqueous solutions and have been tested for the
delivery of hydrophilic and hydrophobic drugs. A
ferrofluid that contains super paramagnetic iron
oxide nanoparticles can be functionated with many
entities, such as an imaging agent and a drug to treat
cancer in one unit. This multifunctional unit possesses
a unique ability to generate heat when exposed to an
alternating magnetic field. Such an ability has a
potential application of not only delivering heat to kill
cancer cells but also delivering a payload of drug to
the tumor, increasing the efficacy of the treatment.14
Heat, or hyperthermia, as therapeutic tool has
been used for the management of cancer for many
years. Previous studies have shown that tumor cells
are more sensitive to heat than normal cells.15–18
Sustained temperatures above 438C sensitize tumor
cells to respond favorably to radiotherapy or chemo-
therapy and produce a direct cytotoxic effect.15,16,18
Over the years, the methods of heat application have
improved from water baths to noncontact heat-
delivery techniques, including radiofrequency, micro-
waves, and focused ultrasound waves. Recently,
magnetic nanoparticles have been used as nano-
heaters in the delivery of heat to targeted tumor cells
without damaging normal tissue. This phenomenon is
commonly known as magnetic hyperthermia.18 Mag-
netic nanoparticles typically have a diameter of 2 to
100 nm and can be coated with a biocompatible
substance to prevent agglomeration. In magnetic
hyperthermia, the application of an alternating
magnetic field to the magnetic nanoparticles leads to
the coupling of magnetic motions of the nanoparticles
with the oscillating field and conversion of the
absorbed energy into heat within the targeted tumor
tissue. Three distinct mechanisms are involved in heat
generation by nanoparticles: Neel relaxation (release
of energy by the rotation of the magnetic moment of
the nanoparticles), Brownian relaxation (release of
the energy by physical rotation of the nanoparticles),
and hysteresis loses (when the magnetism of nano-
particles does not follow the magnetism of the applied
field).17,18
Hyperthermia was previously used in combination
with external beam radiotherapy in the management
of uveal melanoma and retinoblastoma.19 In this
paradigm, local heat is generated via ultrasound and
microwave probes. Finger20 utilized a dish-shaped
microwave antenna that was placed over the sclera
under the tumor at the time of plaque radiotherapy.
This antenna delivered heat at a minimum of 428C for
45 minutes. Hyperthermia in combination with
plaque radiotherapy (thermoradiotherapy) reduced
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the tumor apex dose from 100 Gy to a mean of 53 Gy
and provided a local control rate of 97% at a mean
follow-up of 45 months. In a murine transgenic
retinoblastoma model, Murray et al.21 tested two
ferromagnetic hyperthermia needles placed into the
medial and lateral canthi abutting the globe. After
applying heat for 20 minutes at 488C, retinoblastoma
was cured in 30% of eyes. When the heat increased to
548C, the cure rate improved to 100%. Additionally,
external beam radiation dose for tumor control in
50% of eyes decreased from 27.6 Gy to 3.3 Gy when
combined with magnetic hyperthermia.
Nanoparticles activated by magnetic hyperthermia
can produce reactive oxidative species that lead to
DNA and mitochondrial damage and protein oxida-
tion.22–28 In addition, the activation of the phospha-
tidylinositol 3-kinase/Akt/Bad pathway by magnetic
hyperthermia potentiates the intrinsic proapoptotic
factors cytochrome c, caspase 9, and caspase 3,
causing apoptotic death.22–29 Exposure to a mild heat
shock can activate extrinsic apoptotic signaling via
FAS signaling in cancer cell lines, including Jurkat
and HeLa cells.25 Besides the FAS death receptor,
magnetic nanoparticles have been shown to induce
cell death in human glioma cells via increased tumor
necrosis factor alpha (TNF-a) expression.28
Magnetic nanoparticles as nanoheaters that can
deliver targeted heat to tumor tissue have not been
previously evaluated in the management of retino-
blastoma. With the unique superficial location of the
eye and the advancement of safe intravitreal injection
techniques, magnetic nanoparticles can easily be used
for drug delivery and enhance the effect of current
chemotherapeutics. In this study, we assessed the
apoptotic effect of dextran-coated iron oxide nano-
particles (DCIONs) activated by a magnetic field on a
Y79 retinoblastoma cell line. We evaluated the time
course of cell death and the signaling pathways
activated during magnetic hyperthermia of Y79 cells.
We compared Y79 cell line responses to those seen in
ARPE-19 cell line, an in vitro model of retinal
pigment epithelium (RPE) cells, as a proxy for one
of the retinal cell types that might be adversely




The Y79 retinoblastoma cell line was maintained
as a suspension culture in RPMI 1640 media (catalog
number 30-2001; Invitrogen, Waltham, MA) with 2
mM L-glutamine, 20% heat-inactivated fetal bovine
serum (FBS), 100 U/ml penicillin, and 100 lg/ml
streptomycin. The ARPE-19 retinal pigment epithe-
lium cell line was cultured in 1:1 DMEM:F12 media
(catalog number 30-2006; Invitrogen) containing 2.5
mM L-glutamine, 15 mM HEPES, 10% FBS, 100 U/
ml penicillin, and 100 lg/ml streptomycin. Both cells
lines were plated on 75-cm2 flasks (catalog number
07-202-000; Fisher Scientific, Ann Arbor, MI) and
maintained at 378C in a humidified atmosphere of 5%
CO2 and 95% air until they reached 90% confluency.
Magnetic Hyperthermia
Iron oxide nanoparticles were synthesized using a
standard coprecipitation technique in which an
aqueous solution of FeCl36H2O and FeCl24H2O
were mixed in a 2:1 molar ratio and Fe3O4
nanoparticles were precipitated by the drop-wise
addition of 1M NH4OH. During precipitation, N2
gas was bubbled through the solution to protect
against oxidation of the Fe2þ ions into Fe3þ ions. The
precipitate was separated from the solution by a
strong magnet, washed with deionized water and
resuspended in a metastable 0.5 M NaOH solution. In
order to suspend the precipitated nanoparticles in a
carrier solution (deionized water), they were coated in
dextran by the drop-by-drop addition of the metasta-
ble solution of Fe3O4 to a solution of 15 to 20 kDa
dextran (MP Biomedicals, Santa Ana, CA) in 0.5 M
NaOH while simultaneously probe sonicating.
Y79 retinoblastoma and ARPE-19 cells were
cultured in cryogenic tubes (catalog number 03-337-
7D; Fisher Scientific) at a density of 100,000 cells/ml.
They were incubated for 24 hours prior to treatment.
DCION stock was diluted with the respective culture
media to give a dose of 0.25, 0.5, 0.75, or 1 mg/ml.
After removing the media, cells were treated for 2
hours to allow receptor-mediated endocytosis (cla-
thrin- and caveolae-mediated endocytosis) in the
dose-dependent concentration of nanoparticles, as
shown in multiple previous studies.29,30 After 2 hours
of incubation, media with nanoparticles were re-
moved and fresh media were added. Cells were then
treated using a magnetic field with the frequency and
intensity values of 250 kHz and 4 kA/m. After
reaching a temperature varying between 42 and
468C, the electromagnetic gradient was kept constant
for 30 minutes. Temperature was measured using a
fiber optic thermometer (Optocon AG, Dresden,
Germany). Controls were untreated Y79 and
ARPE-19 cells and those incubated with respective
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concentrations of nanoparticles without magnetic
hyperthermia.
Cell Viability and Caspase Activity Assays
Hyperthermia-induced apoptosis was assessed at 4,
24, and 72 hours after treatment for both Y79 and
ARPE-19 cells. The numbers of viable cells were
measured based on quantitation of adenosine tri-
phosphate by using the CellTiter-Glo Luminescent
Cell Viability Assay kit (catalog number G7571;
Promega, Madison, WI) following the manufacturer’s
recommendations. Caspase 8 or 3/7 activity of Y79
cells at the nanoparticle concentration of 1 mg/ml was
measured according to manufacturer’s instructions
after 48 hours of treatment by using the Caspase-Glo
8 or 3/7 Assay kit (Promega). Luminescence was
measured using a Veritas Microplate luminometer
(Turner Biosystems, Sunnyvale, CA).
Transmission Electron Microscopy (TEM)
Imaging of DCION Uptake
TEM was performed to elucidate the cellular
uptake and distribution of nanoparticles. Y79 and
ARPE-19 cells were cultured in Corning 100-mm
plates (catalog number 430167; Fisher Scientific) for
24 hours, after which they were incubated with 1 mg/
ml of nanoparticles for 2 hours. After treatment, cells
were collected and fixed in 2.5% glutaraldehyde and
subsequently postfixed using 1% osmium tetroxide for
3 hours, and then pelleted, dehydrated, infiltrated,
and embedded. Finally, ultrathin sections were cut
and stained with uranyl acetate. TEM images were
taken using a Hitachi HT7700 transmission electron
microscope (Tokyo, Japan).
PCR Assay for Apoptosis Gene Profiling
Y79 retinoblastoma cells were treated with 1 mg/
ml of DCION followed by the induction of a
magnetic field to create hyperthermia. The cells were
further incubated for 24 hours after magnetic
induction. Total RNA was extracted using the
RNeasy mini kit (catalog number 74104; Qiagen,
Germantown, MD). A total of 25 ng of complemen-
tary DNA (cDNA) was then synthesized and pre-
amplified using the RT2 PreAMP cDNA Synthesis kit
(catalog number 330451; Qiagen) following the
manufacturer’s instructions. A solution of 25 ll made
of the amplified cDNA diluted with nuclease-free
water and RT2 SYBR Green qPCR Mastermix
(catalog number 330502; Qiagen) was added to each
well of the RT2 Profiler PCR Array Human
Apoptosis (catalog number PAHS-012Z; Qiagen)
plate. Real-time PCR was performed on a CFX96
PCR system (Bio-Rad Laboratories, Hercules, CA)
by using SYBR green detection. The thermocycler
parameters consisted of an initial denaturation at
958C for 10 minutes followed by 39 cycles at 958C for
15 seconds and annealing at 608C for 1 minute. The
dissociation curve was at 958C for 1 minute, 558C for
30 seconds, and 958C for 30 seconds. All quality-
control requirements stated by the manufacturer were
fulfilled in the PCR runs (including genomic DNA
control, cDNA synthesis control, and positive PCR
controls). Relative changes in gene expression were
calculated using the delta delta cycle threshold (DDCt)
method using SA Bioscience’s PCR Array Data
Analysis Web Portal. Gene set enhancement analysis
was performed by using web tools, including www.
reactome.org and toppgene.cchmc.org. The pathways
found to be statistically significant were reported.
Data Analysis
Data were analyzed using one-way analysis of
variance followed by Tukey’s post hoc test. A value of
P , 0.05 was considered significant. Prism 7.0
(GraphPad Software, San Diego, CA) was used for
all statistical analyses. Results are expressed as mean
6 standard error of the mean.
Results
We first tested the viability of Y79 retinoblastoma
and ARPE-19 RPE cell lines by using different
DCION concentrations at 4, 24, and 72 hours
following magnetic hyperthermia treatment (Fig. 1).
A time- and concentration-dependent cell death was
observed in Y79 cells after the application of
alternating electromagnetic field. At 4 hours following
magnetic hyperthermia, cell death for Y79 cells was
1%, 8%, 17%, and 17% for 0.25, 0.5, 0.75, and 1 mg/
ml of DCION concentration, respectively. At 24
hours, cell death in Y79 cells was 47%, 59%, 70%, and
75%, and at 72 hours, cell death was 16%, 45%, 50%,
and 56% at DCION concentrations of 0.25, 0.5, 0.75,
and 1 mg/ml, respectively. More than half of cells
were dead when exposed to 0.75 and 1 mg/ml of
DCION concentrations after 24 and 72 hours. In
contrast, ARPE-19 cells remained viable up to 88% at
0.25, 0.5, and 0.75 mg/ml of DCION concentrations
following magnetic hyperthermia after 24 and 72
hours. There was minimal cytotoxicity of iron oxide
nanoparticles to Y79 or ARPE-19 cells for all
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Figure 1. ARPE-19 and Y79 retinoblastoma cells were treated with iron oxide nanoparticles, and viability was measured with or without
magnetic hyperthermia at 4 (A), 24 (B), and 72 (C) hours. n¼ 3, mean 6 SEM, *P , 0.05, **P , 0.005, ***P , 0.0005, ****P , 0.0001 for
each time point, Tukey test, N ¼ 3.
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concentrations tested in the absence of magnetic
hyperthermia (Fig. 1).
We evaluated the expression of genes involved in
cell death pathways 24 hours after magnetic hyper-
thermia in Y79 retinoblastoma cells (Fig. 2). Gene set
enhancement analysis confirmed the activation of
several genes involved in cell death mediated by death
receptor signaling, including FAS and TNF-a path-
ways. FASLG, TNF, TNFRSF9, and TNFRSF1A,
genes involved in FAS and TNF pathways, were
expressed at significantly higher levels in Y79
retinoblastoma cells treated with magnetic hyperther-
mia compared to untreated cells (Table 1). We also
measured the effect of DCION exposure alone on
gene expression by comparing Y79 retinoblastoma
cells treated with or without magnetic hyperthermia.
Again, we found that the levels of FASLG, TNF,
TNFRSF9, and TNFRSF1A were significantly elevat-
ed after magnetic hyperthermia in Y79 cells when
compared to cells exposed to DCION alone (Table 2).
Our data demonstrate a global increase in cell death
gene expression after magnetic hyperthermia in
retinoblastoma cells. This activation leads to a major
shift in apoptotic signaling pathways and leads to
increased cell death, consistent with the loss of cell
viability seen specifically in Y79 cells exposed to
DCION-mediated hyperthermia (Fig. 1). Tables 1
and 2 include the top 25 genes seen in our expression
profiling experiments. The full list of genes that
respond to magnetic hyperthermia after DCION
treatment is presented in supplemental Tables 1 and 2.
To confirm the activation of apoptosis, we
evaluated caspase 8 and 3/7 activities at 48 hours
after magnetic hyperthermia. Caspase 3/7 activity
levels were significantly elevated in Y79 cells treated
with the magnetic hyperthermia compared to control
cells or cells treated with magnetic nanoparticles alone
(Fig. 3). In contrast, caspase 8 activity did not
increase in Y79 cells after magnetic hyperthermia
(Fig. 3). This suggests that the intrinsic apoptotic
pathway mediated by mitochondria is the primary cell
death mechanism in Y79 cells following hyperthermic
insult induced by magnetic nanoparticles.
We next evaluated the localization of DCIONs in
Y79 and ARPE-19 cells using TEM. Our data show
that nanoparticles were engulfed by both Y79 and
ARPE-19 cells (Fig. 4). In ARPE-19 cells, DCIONs
were located in lysosomes and endosomes in the
Figure 2. Volcano plot of gene expression profiling showing Y79
retinoblastoma cells exposed to iron oxide nanoparticles versus
untreated Y79 retinoblastoma cells (A), Y79 retinoblastoma cells
exposed to magnetic hyperthermia using iron oxide nanoparticles
versus Y79 retinoblastoma cells without iron oxide nanoparticles
exposure (B), Y79 retinoblastoma cells exposed to magnetic
hyperthermia using iron oxide nanoparticles versus Y79
retinoblastoma cells exposed to iron oxide nanoparticles without
magnetic field exposure (C). Genes with a 30-fold or larger increase
 
in messenger RNA (mRNA) levels with a P value of ,0.05 are
indicated in red and names are shown. FC, Fold change.
6 TVST j 2019 j Vol. 8 j No. 5 j Article 18
Demirci et al.
Downloaded from tvst.arvojournals.org on 11/24/2021
cytoplasm, whereas nanoparticles were distributed
throughout cellular structures in Y79 cells.
Discussion
Previous studies have shown that 438C is a critical
temperature for the survival of normal and cancer
cells. A review of the literature by Leith et al.22
demonstrated that cell survival decreases exponen-
tially as a function of exposure time at temperatures
above 418C in multiple cancer cell lines, including
HeLa, L1210 leukemia, EMT6 mouse mammary
sarcoma, and malignant liver cells.22–24 Additionally,
at the temperatures 438C or above, cell death
increased by a factor of 2 for every 18C increase in
temperature.22–24 When the effects of hyperthermia
and thermal tolerance were evaluated in the normal
human fibroblast cell lines, Rassphorst and Azzam25
observed that fibroblasts developed thermal tolerance
Table 1. Top 25 Genes Upregulated 24 Hours After
Magnetic Hyperthermia in Y-79 Retinoblastoma Cells





FASLG FAS ligand 1133.0533
TNF Tumor necrosis factor 665.9792
IL10 Interleukin 10 646.273
BAG3 BCL2 associated athanogene 3 583.8012
CASP14 Caspase 14 317.2186
TNFRSF9 TNF receptor superfamily
member 9
269.2246
PYCARD PYD and CARD domain
containing
265.5181
LTBR Lymphotoxin beta receptor 258.2575
BCL2A1 BCL2 related protein A1 140.0049
LTA Lymphotoxin alpha 130.0269
BIRC3 Baculoviral IAP repeat
containing 3
112.9338
CFLAR CASP8 and FAAD-like apoptosis
regulator
97.4101
CD70 CD70 molecule 52.6855
CD40 CD40 molecule 47.9237
CASP10 Caspase 10 44.4055
BCL2L10 BCL2 like 10 38.037
CD40LG CD40 ligand 37.1683
CASP5 Caspase 5 35.2447
TNFRSF1A TNF receptor superfamily
member 1A
32.9605
FAS FAS cell surface death receptor 32.1334
CASP8 Caspase 8 31.8378
HRK Harakiri, BCL2 interacting
protein
31.7643
CD27 CD27 molecule 25.0372
TNFSF10 TNF superfamily member 10 24.7496
CASP4 Caspase 4 24.1285
Table 2. Top 25 Genes Upregulated 24 Hours After
Magnetic Hyperthermia in Y-79 Retinoblastoma Cells
Treated With 1 mg/ml of DCIONs Compared to Y-79





TNF Tumor necrosis factor 964.3592
FASLG FAS ligand 800.8011
BAG3 BCL2 associated athanogene 3 632.7203
IL10 Interleukin 10 543.3515
CASP14 Caspase 14 369.8034
PYCARD PYD and CARD domain
containing
157.6189
TNFRSF9 TNF receptor superfamily
member 9
129.4063
LTA Lymphotoxin alpha 117.7604
LTBR Lymphotoxin beta receptor 90.524
BIRC3 Baculoviral IAP repeat
containing 3
83.6729
CD40LG CD40 ligand 76.4886
CFLAR CASP8 and FADD like
apoptosis regulator
70.8628
BCL2A1 BCL2 related protein A1 60.5563
BCL2L10 BCL2 like 10 53.2101
TNFRSF1A TNF receptor superfamily
member 1A
48.284
FAS FAS cell surface death receptor 45.187
CD40 CD40 molecule 42.9574
RIPK2 Receptor interacting serine/
threonine kinase 2
37.947
CASP10 Caspase 10 37.6304
CD70 CD70 molecule 34.8205
TNFSF8 TNF superfamily member 8 34.6293
CASP4 Caspase 4 34.1119
CD27 CD27 molecule 33.7515
HRK Harakiri, BCL2 interacting
protein
26.8848
TNFRSF10A TNF receptor superfamily
member 10a
21.4137
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without heat damage. Less than 10% cell death was
recorded after 6 to 8 hours of intracellular heating at
temperatures less than or equal to 438C. Between the
temperatures of 43 and 448C, thermal tolerance
developed after 2 hours of heating and lasted up to
6 hours. All these experiments were performed with
water baths or microwave probes. It is postulated that
cancer tissues are relatively hypoxic and acidic
secondary to inefficient vascular channels.25 When
exposed to thermal insult, this vascular insufficiency
leads to impaired cooling in tumor tissue compared to
normal tissue, increasing the sensitivity of cancer to
thermal injury.25 The exact molecular mechanisms of
how thermal injury selectively kills tumor cells are
largely unknown.
Nanotechnology provides a novel tool for mag-
netic hyperthermia. Since the first studies by Gordon
et al.,26 iron oxide-based nanoparticles with superior
magnetic and functionalized surface properties have
been used for magnetic hyperthermia in targeted
cancer treatment.27,28 Ito and Kobayashi31 evaluated
the efficacy of magnetic hyperthermia by using
dextran-coated magnetic nanoparticles in animals
with various tumors, including B16 mouse melanoma,
MM46 mouse mammary carcinoma, PC3, and
LNCaP human prostate cancer in athymic mice,
spontaneously occurring primary melanoma in trans-
genic mice, T-9 rat glioma, rat prostate cancer PLS10,
Os515 hamster osteosarcoma, VX-7 squamous cell
carcinomas in rabbit tongue, and human breast
cancer BT474 (HER2-positive) in nude mice. Direct
injection of nanoparticles into the solid tumor
followed by magnetic hyperthermia application led
to complete tumor regression in 96% of animals. In a
clinical trial, Maier-Hauff et al.32 performed intra-
tumoral injection of iron-oxide nanoparticles in 59
patients with recurrent glioblastoma multiforme.
Magnetic hyperthermia was coupled with a reduced
dose of fractionated stereotactic radiotherapy (a
median dose of 30 Gy). The median overall survival
of patients was 13.4 months, which was considerably
longer than the typical median survival of 6 months in
patients undergoing conventional radiotherapy.
In this paper, we present the first evaluation of
magnetic hyperthermia using dextran-coated iron
nanoparticles in a retinoblastoma cell line. At 24
hours, one session of magnetic hyperthermia induced
46% to 73% of death in Y79 retinoblastoma cells,
suggesting that apoptosis started less than 24 hours
after magnetic induction (Fig. 1). Effective cell death
was observed with 0.75 and 1 mg/ml of nanoparticle
concentration at 24 and 72 hours after magnetic
hyperthermia. We observed maximum tumor cyto-
toxicity at 24 hours. Decreased cell death at 72 hours
may indicate that surviving tumor cells continue to
proliferate, selecting for resistant cell types. There was
minimal cytotoxicity in ARPE-19 cells after 24 and 72
hours of magnetic hyperthermia at all nanoparticle
concentrations, demonstrating that magnetic hyper-
thermia selectively induces cell death in tumor cells in
a dose- and time-dependent manner. Our data
demonstrate that optimal nanoparticle concentration
for tumor cytotoxicity, while having a minimal
cytotoxic effect on nontumor cells, was 0.75 mg/ml.
However, we acknowledge that there are inherent
caveats of studying cytotoxic effects of magnetic
hyperthermia in in vitro cell culture systems. The
differences in cell culture media (10% FBS for ARPE-
19 vs. 20% for Y79 cells) and morphologic changes
that occur in ARPE-19 cells upon moving from
adherent cultures to suspensions in cryotubes may
influence the uptake of nanoparticles, which might
affect cytotoxicity.
We observed that dextran-coated nanoparticles are
Figure 3. Y79 cell viability (A) and caspase activity (B) 48 hours following magnetic hyperthermia using iron oxide nanoparticles at a
concentration of 1 mg/mL. n ¼ 3, mean 6 SEM, **P , 0.005, ****P , 0.0001 compared to control, Tukey test, N ¼ 3.
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engulfed in the cytoplasm, lysosomes, and endosomes
of the ARPE-19 and Y79 cells. Overgaards33 evalu-
ated the ultrastructural changes in mouse mammary
carcinoma after hyperthermia. The authors first
observed a decrease in cell size with an increase in
the number and activity of cytoplasmic lysosomes and
disaggregated polyribosomes in the first 6 hours. This
was followed by cell shrinkage and reduction in the
number of mitochondria within 6 to 24 hours and
total disarrangement of cytoplasmic components in
24 hours. Magnetic nanoparticles induced ruffling of
the cell surface, which resulted from internalization
Figure 4. Electron microscopy showed that nanoparticles are engulfed by both ARPE-19 and Y79 cells. The magnetic nanoparticles are
located in endosomes and lysosomes throughout the cytoplasm in ARPE-19 cells (arrows, A and B) and Y79 retinoblastoma cells (arrows,
C and D).
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via micropinocytosis, forming endosomes.34–36 With
magnetic hyperthermia, nanoparticles leaked into the
cytoplasm and produced reactive oxidative species,
which led to DNA and mitochondrial damage and
protein oxidation. Fang et al.37 proposed that
magnetic nanoparticles increase the activation of the
phosphatidylinositol 3-kinase/Akt/Bad pathway in
LOVO cells, leading to the expression of cytochrome
c, caspase 9, and caspase 3 proteins. Using TEM, we
observed magnetic nanoparticles that were internal-
ized into Y79 retinoblastoma cells. Forty-eight hours
after the application of magnetic hyperthermia,
caspase 3/7 activity increased selectively in tumor
cells, indicating the activation of the mitochondrial
cell death pathway. We also observed significant
changes in the expression of apoptotic genes, includ-
ing those involved in FAS and TNF-a signaling. Our
gene expression data demonstrated that many signal-
ing pathways involved in cell death were significantly
elevated in tumor cells specifically after magnetic
hyperthermia. This global change in apoptotic and
antiapoptotic gene expression suggests that internal-
ization of nanoparticles and magnetic hyperthermia
lead to catastrophic cell damage and kill Y79 cells via
both extrinsic and intrinsic apoptotic pathways.
Death receptors, such as the FAS and TNF
receptors (FASR, and TNF-R1), are membrane
proteins capable of inducing apoptosis and belong
to the TNF-R superfamily.38 Following magnetic
hyperthermia, gene expression profiling showed that
genes in FAS and TNF-a signaling pathways were
highly activated in Y79 retinoblastoma cells, reaching
several hundred folds for some genes, including FAS
ligand and TNF. Tran et al.39 showed that exposure
to mild heat shock (30 minutes at 428C) rapidly
activated FAS-mediated apoptosis in cancer lines,
including Jurkat and HeLa cells. FAS activates
caspase-3 not only by inducing the cleavage of the
caspase zymogen to its active subunits but also by
stimulating the denitrosylation of its active-site
thiol.40,41 In nude mice carrying human glioma cells,
Ito et al.42 showed that hyperthermia using magnetic
nanoparticles induced cell death throughout the
tumor area and increased TNF-a gene expression by
3-fold. Our results indicate that FAS and TNF-a
pathways are the primary drivers of apoptosis after
magnetic hyperthermia treatment in Y79 cells.
Our data demonstrated that DCION treatment had
a minimal cytotoxic effect on Y79 or ARPE-19 cells in
the absence of magnetic hyperthermia. We found that
magnetic hyperthermia via iron nanoparticles was
selectively cytotoxic to Y79 retinoblastoma cells,
providing evidence for developing magnetic hyperther-
mia as a potential treatment for retinoblastoma. In
addition, we did not detect any caspase activation with
iron nanoparticles in the absence of magnetic treat-
ment, demonstrating that hyperthermia is the primary
mechanism of tumor toxicity in our model.
Dextran-coated nanoparticles and magnetic hyper-
thermia might have clinical applications for intraoc-
ular tumors. Because intraocular injection is a
commonly-used procedure for many retinal diseases,
dextran-coated nanoparticles can be easily delivered
intravitreally by using existing techniques. Nanopar-
ticle-mediated magnetic hyperthermia can be used as
an adjuvant therapy to enhance the outcome of
chemotherapy or radiotherapy for eliminating intra-
ocular tumors. However, the penetration of intra-
vitreally delivered dextran-coated nanoparticles into
the retinal tissue and the choroid and potential ocular
toxicity are unknown. Further studies, including
those involving animal models of intraocular tumors,
are needed to answer these questions. Modifying
nanoparticles with fluorescent labels and staining
retinoblastoma tissue with various organelle-specific
stains in animal models will also be needed to
determine the exact subcellular localization of nano-
particles in in vivo applications.
In summary, similar to other cancer cells, Y79
retinoblastoma cells are exquisitely sensitive to
thermal damage. We demonstrate that magnetic
hyperthermia using dextran-coated iron nanoparticles
selectively kills retinoblastoma cells in a dose- and
time-dependent manner in vitro, while sparing non-
tumor cells. Magnetic hyperthermia induces apoptotic
cell death in Y79 cells primarily via the intrinsic
pathway activated by FAS and TNF-a signaling.
With the recent advent of intravitreal chemothera-
peutic injections in the management of retinoblasto-
ma, magnetic hyperthermia with dextran-coated iron
nanoparticles may be a promising therapeutic option.
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